Literature DB >> 20080637

MYCN-regulated microRNAs repress estrogen receptor-alpha (ESR1) expression and neuronal differentiation in human neuroblastoma.

Jakob Lovén1, Nikolay Zinin, Therese Wahlström, Inga Müller, Petter Brodin, Erik Fredlund, Ulf Ribacke, Andor Pivarcsi, Sven Påhlman, Marie Henriksson.   

Abstract

MYCN, a proto-oncogene normally expressed in the migrating neural crest, is in its amplified state a key factor in the genesis of human neuroblastoma (NB). However, the mechanisms underlying MYCN-mediated NB progression are poorly understood. Here, we present a MYCN-induced miRNA signature in human NB involving the activation and transrepression of several miRNA genes from paralogous clusters. Several family members derived from the miR-17 approximately 92 cluster, including miR-18a and miR-19a, were among the up-regulated miRNAs. Expression analysis of these miRNAs in NB tumors confirmed increased levels in MYCN-amplified samples. Specifically, we show that miR-18a and miR-19a target and repress the expression of estrogen receptor-alpha (ESR1), a ligand-inducible transcription factor implicated in neuronal differentiation. Immunohistochemical staining demonstrated ESR1 expression in human fetal sympathetic ganglia, suggesting a role for ESR1 during sympathetic nervous system development. Concordantly, lentiviral restoration of ESR1 in NB cells resulted in growth arrest and neuronal differentiation. Moreover, lentiviral-mediated inhibition of miR-18a in NB cells led to severe growth retardation, outgrowth of varicosity-containing neurites, and induction of neuronal sympathetic differentiation markers. Bioinformatic analyses of microarray data from NB tumors revealed that high ESR1 expression correlates with increased event-free survival in NB patients and favorable disease outcome. Thus, MYCN amplification may disrupt estrogen signaling sensitivity in primitive sympathetic cells through deregulation of ESR1, thereby preventing the normal induction of neuroblast differentiation. Collectively, our findings demonstrate the molecular consequences of abnormal miRNA transcription in a MYCN-driven tumor and offer unique insights into the pathology underlying MYCN-amplified NB.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20080637      PMCID: PMC2824410          DOI: 10.1073/pnas.0913517107

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  45 in total

1.  Mnt transcriptional repressor is functionally regulated during cell cycle progression.

Authors:  Nikita Popov; Therese Wahlström; Peter J Hurlin; Marie Henriksson
Journal:  Oncogene       Date:  2005-12-15       Impact factor: 9.867

2.  Prediction of mRNA polyadenylation sites by support vector machine.

Authors:  Yiming Cheng; Robert M Miura; Bin Tian
Journal:  Bioinformatics       Date:  2006-07-26       Impact factor: 6.937

Review 3.  Estrogen carcinogenesis in breast cancer.

Authors:  James D Yager; Nancy E Davidson
Journal:  N Engl J Med       Date:  2006-01-19       Impact factor: 91.245

4.  25 years of the c-Myc oncogene.

Authors:  Michael D Cole; Marie Henriksson
Journal:  Semin Cancer Biol       Date:  2006-08-11       Impact factor: 15.707

5.  Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that multiple genes are targeted by regional alterations in DNA copy number.

Authors:  Qun Wang; Sharon Diskin; Eric Rappaport; Edward Attiyeh; Yael Mosse; Daniel Shue; Eric Seiser; Jayanti Jagannathan; Suzanne Shusterman; Manisha Bansal; Deepa Khazi; Cynthia Winter; Erin Okawa; Gregory Grant; Avital Cnaan; Huaqing Zhao; Nai-Kong Cheung; William Gerald; Wendy London; Katherine K Matthay; Garrett M Brodeur; John M Maris
Journal:  Cancer Res       Date:  2006-06-15       Impact factor: 12.701

Review 6.  A small piece in the cancer puzzle: microRNAs as tumor suppressors and oncogenes.

Authors:  O A Kent; J T Mendell
Journal:  Oncogene       Date:  2006-10-09       Impact factor: 9.867

Review 7.  Neuroblastoma as an experimental model for neuronal differentiation and hypoxia-induced tumor cell dedifferentiation.

Authors:  Anders Edsjö; Linda Holmquist; Sven Påhlman
Journal:  Semin Cancer Biol       Date:  2006-05-10       Impact factor: 15.707

Review 8.  The c-Myc target gene network.

Authors:  Chi V Dang; Kathryn A O'Donnell; Karen I Zeller; Tam Nguyen; Rebecca C Osthus; Feng Li
Journal:  Semin Cancer Biol       Date:  2006-07-25       Impact factor: 15.707

9.  Customized oligonucleotide microarray gene expression-based classification of neuroblastoma patients outperforms current clinical risk stratification.

Authors:  André Oberthuer; Frank Berthold; Patrick Warnat; Barbara Hero; Yvonne Kahlert; Rüdiger Spitz; Karen Ernestus; Rainer König; Stefan Haas; Roland Eils; Manfred Schwab; Benedikt Brors; Frank Westermann; Matthias Fischer
Journal:  J Clin Oncol       Date:  2006-11-01       Impact factor: 44.544

10.  Differential patterns of microRNA expression in neuroblastoma are correlated with prognosis, differentiation, and apoptosis.

Authors:  Yongxin Chen; Raymond L Stallings
Journal:  Cancer Res       Date:  2007-02-01       Impact factor: 12.701

View more
  67 in total

1.  PLEKHA7 defines an apical junctional complex with cytoskeletal associations and miRNA-mediated growth implications.

Authors:  Antonis Kourtidis; Panos Z Anastasiadis
Journal:  Cell Cycle       Date:  2016       Impact factor: 4.534

Review 2.  Functional interactions among members of the miR-17-92 cluster in lymphocyte development, differentiation and malignant transformation.

Authors:  Maoyi Lai; Changchun Xiao
Journal:  Int Immunopharmacol       Date:  2015-04-11       Impact factor: 4.932

3.  A neurogenetics approach to defining differential susceptibility to institutional care.

Authors:  Zoe H Brett; Margaret Sheridan; Kate Humphreys; Anna Smyke; Mary Margaret Gleason; Nathan Fox; Charles Zeanah; Charles Nelson; Stacy Drury
Journal:  Int J Behav Dev       Date:  2015-03

4.  The c-Myc-regulated microRNA-17~92 (miR-17~92) and miR-106a~363 clusters target hCYP19A1 and hGCM1 to inhibit human trophoblast differentiation.

Authors:  Premlata Kumar; Yanmin Luo; Carmen Tudela; James M Alexander; Carole R Mendelson
Journal:  Mol Cell Biol       Date:  2013-02-25       Impact factor: 4.272

Review 5.  The role of genetic and epigenetic alterations in neuroblastoma disease pathogenesis.

Authors:  Raquel Domingo-Fernandez; Karen Watters; Olga Piskareva; Raymond L Stallings; Isabella Bray
Journal:  Pediatr Surg Int       Date:  2012-12-29       Impact factor: 1.827

6.  A microRNA negative feedback loop downregulates vesicle transport and inhibits fear memory.

Authors:  Rebecca S Mathew; Antonis Tatarakis; Andrii Rudenko; Erin M Johnson-Venkatesh; Yawei J Yang; Elisabeth A Murphy; Travis P Todd; Scott T Schepers; Nertila Siuti; Anthony J Martorell; William A Falls; Sayamwong E Hammack; Christopher A Walsh; Li-Huei Tsai; Hisashi Umemori; Mark E Bouton; Danesh Moazed
Journal:  Elife       Date:  2016-12-21       Impact factor: 8.140

7.  Primate-specific miR-515 family members inhibit key genes in human trophoblast differentiation and are upregulated in preeclampsia.

Authors:  Ming Zhang; Sribalasubashini Muralimanoharan; Alison C Wortman; Carole R Mendelson
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-24       Impact factor: 11.205

8.  MicroRNA expression is differentially altered by xenobiotic drugs in different human cell lines.

Authors:  Alice C Rodrigues; Xin Li; Laura Radecki; Yu-Zhuo Pan; Jerrold C Winter; Min Huang; Ai-Ming Yu
Journal:  Biopharm Drug Dispos       Date:  2011-07-28       Impact factor: 1.627

9.  Functional MYCN signature predicts outcome of neuroblastoma irrespective of MYCN amplification.

Authors:  Linda J Valentijn; Jan Koster; Franciska Haneveld; Rachida Ait Aissa; Peter van Sluis; Marloes E C Broekmans; Jan J Molenaar; Johan van Nes; Rogier Versteeg
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-22       Impact factor: 11.205

10.  LIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppression.

Authors:  Jan J Molenaar; Raquel Domingo-Fernández; Marli E Ebus; Sven Lindner; Jan Koster; Ksenija Drabek; Pieter Mestdagh; Peter van Sluis; Linda J Valentijn; Johan van Nes; Marloes Broekmans; Franciska Haneveld; Richard Volckmann; Isabella Bray; Lukas Heukamp; Annika Sprüssel; Theresa Thor; Kristina Kieckbusch; Ludger Klein-Hitpass; Matthias Fischer; Jo Vandesompele; Alexander Schramm; Max M van Noesel; Luigi Varesio; Frank Speleman; Angelika Eggert; Raymond L Stallings; Huib N Caron; Rogier Versteeg; Johannes H Schulte
Journal:  Nat Genet       Date:  2012-10-07       Impact factor: 38.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.